WILMINGTON, Del., Sept. 20, 2016 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announces that a securities fraud class action lawsuit has been filed by another law firm on behalf of shareholders of Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”) for possible corporate misconduct and violations of securities laws.
A copy of the complaint is available from the Court or from Andrews & Springer LLC. If you currently own shares of Sientra and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/sientra-class-action-investigation or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
On November 5, 2015, a Sientra shareholder, represented by another law firm, filed a class action complaint against Sientra for securities fraud. The complaint was filed in the California Superior Court, San Mateo County, Case No. 536138.
According to the lawsuit, Sientra and certain of its executive officers made a series of false and misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the defendants are alleged to have made false and misleading statements and/or failed to disclose that: (i) Sientra’s exclusive reliance on Silimed’s Brazilian manufacturing facilities carried significant quality control risks; (ii) the manufacturing processes at the Silimed Rio de Janeiro manufacturing plant were contaminated; and (iii) as a result of the above, the Company’s statements regarding quality control and other financial statements were materially false and misleading at all relevant times.
On September 24, 2015, it was announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) had suspended sales of Silimed products after an audit of Silimed’s manufacturing processes revealed contamination in Silimed’s Rio de Janeiro manufacturing plant.
Following this news, shares of Sientra’s common stock declined $10.88 per share, or nearly 53%, to close at $9.70 per share on September 24, 2015.
If you currently own shares of Sientra and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/sientra-class-action-investigation or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Toll Free: 1-800-423-6013


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Apple Turns 50: From Garage Startup to AI Crossroads
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 



